Abstract
High-dose stereotactic body radiation therapy (SBRT) yields very high rates of biochemical control for low- (LR) and intermediate-risk (IR) prostate cancer (PCa), but in our prior Phase 1/2 trial of SBRT for LR and IR PCa a degree of rectal injury (e.g., mucosal erosion or ulcer) was observed in all cases, with potential high grade toxicity associated with incidental dose to the rectal wall. We report outcomes of a multi-institutional phase 2 clinical trial of high-dose SBRT for LR and IR PCa patients following placement of a peri-rectal hydrogel spacer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
